Use of thalidomide in dermatological indications

Area of Science:

• Immunology
• Pharmacology
• Dermatology

Background:

• Thalidomide use has surged for conditions like HIV-associated dermatoses, Behçet's disease, graft-versus-host disease, and systemic lupus erythematosus.
• Initial use stemmed from uncontrolled studies in treatment-resistant cases, with recent trials validating its efficacy for prevalent indications.

Purpose of the Study:

• To explore the molecular mechanisms underlying thalidomide's therapeutic effects.
• To assess the potential for expanding thalidomide and its analogues to new therapeutic areas.

Main Methods:

• In vivo studies demonstrating partial inhibition of tumor necrosis factor-alpha (TNF-α).
• In vitro studies investigating thalidomide's role in T cell activation and cytokine production (interleukin-2, interferon-gamma).

Main Results:

• Thalidomide partially inhibits TNF-α production in vivo.
• In vitro, thalidomide acts as a co-stimulatory molecule for T cell activation, enhancing interleukin-2 and interferon-gamma production.
• Beyond monocyte inhibition, thalidomide exhibits co-stimulatory or adjuvant-like effects on T cell responses.

Conclusions:

• Understanding thalidomide's molecular actions, including T cell co-stimulation, supports its expanded use in various conditions.
• Physicians must be fully aware of thalidomide's risks and adverse effects despite its therapeutic promise.